Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study

PURPOSE: Immune checkpoint inhibition has been demonstrated to be an effective anticancer strategy. Several lines of evidence support the study of immunotherapy in triple-negative breast cancer (TNBC). We assessed the safety and antitumor activity of the programmed cell death protein 1 (PD-1) inhibi...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Clin Oncol
Main Authors: Nanda, Rita, Chow, Laura Q.M., Dees, E. Claire, Berger, Raanan, Gupta, Shilpa, Geva, Ravit, Pusztai, Lajos, Pathiraja, Kumudu, Aktan, Gursel, Cheng, Jonathan D., Karantza, Vassiliki, Buisseret, Laurence
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2016
Teme:
ORIGINAL REPORTS
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6816000/
https://ncbi.nlm.nih.gov/pubmed/27138582
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2015.64.8931
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki